Clinical trials: Degenerative Neurologic Disease
Generalized Myasthenia Gravis
Monitor the Evolution of Myasthenia Gravis Symptoms in Real-life in Patients With Anti-AChR and Anti-MUSK Generalised Myasthenia Gravis in Therapy With RYSTIGGO® (Rozanolixizumab)
Generalized Myasthenia Gravis (gMG) is a rare autoimmune disease (a disease in which the body attacks its own tissues) that causes muscle weakness and significant fatigue.
- Trial name
- REAL MG PRO (NCT07570589)
- Testing
- Patients diagnosed with generalized myasthenia gravis and treated with Rozanolixizumab
- Where
- 11 sites in France
- Volunteers
- 50 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Alzheimer Disease, Late Onset
Does BCG Vaccination Reduce Biomarkers of Alzheimer's Disease?
The goal of this clinical trial is to test whether vaccination with the BCG vaccine may improve the blood level of a biomarker of Alzheimer's disease (AD) in participants who are cognitively- and functionally- intact elderly…
- Trial name
- BCG-AD (NCT06078891)
- Testing
- BCG vaccine
- Where
- Israel
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Tamir Ben-Hur
Amyotrophic Lateral Sclerosis
Extension Study of Talampanel for Amyotrophic Lateral Sclerosis (ALS)
This will be an open label treatment extension phase in patients with ALS who have previously participated in the double blind, placebo-controlled ALS-TAL-201 study.
- Trial name
- ALSTAR OL (NCT00982150)
- Testing
- Talampanel
- Volunteers
- 446 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Loss of Consciousness, Parkinson Disease
Brain Networks and Consciousness
General anesthesia (GA) is a medically induced state of unresponsiveness and unconsciousness, which millions of people experience every year.
- Conditions
- Loss of Consciousness, Parkinson Disease, Essential Tremor, Anesthesia
- Trial name
- NCT04502550
- Testing
- Propofol
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- University of Texas Southwestern Medical Center
Huntington's Disease
A Study in Subjects With Late Prodromal & Early Manifest HD to Assess the Safety, Tolerability, pk, and Efficacy of Pepi
The purpose of this study is to evaluate the safety, tolerability, PK, and efficacy of Pepinemab in subjects with late prodromal and early manifest Huntington's disease.
- Trial name
- SIGNAL-HD (NCT02481674)
- Testing
- VX15/2503
- Where
- 32 sites in United States, Canada
- Volunteers
- 301 people
- Sponsor
- Vaccinex Inc.
Parkinson's Disease
A Study To Evaluate The Safety And Efficacy Of IPX066 In Advanced Parkinson's Disease (ADVANCE-PD).
This is a study to evaluate the safety and efficacy of IPX066 in advanced Parkinson's disease.
- Trial name
- NCT00974974
- Testing
- IPX066, IR CD-LD
- Where
- 73 sites in United States, Canada and 6 more
- Volunteers
- 471 people
- Sponsor
- Impax Laboratories, LLC
Mild Cognitive Impairment (MCI), Subjective Cognitive Complaints (SCCs)
EARLY-COGN^3 - Smart Digital Solutions for EARLY Treatment of COGnitive Disability: a Neuropsychological, Neurophysiological and Neurobiological Perspective in Chronic Neurological Diseases - PNRR-MCNT2-2023-12377069
The increase in life expectancy in recent decades has led to a large number of people living into old age and an increased risk of developing Chronic Neurological Diseases (CNDs) such as neurodegenerative diseases.
- Conditions
- Mild Cognitive Impairment (MCI), Subjective Cognitive Complaints (SCCs), Parkinson Disease
- Trial name
- EARLY-COGN^3 (NCT06657274)
- Testing
- RICORDO-DTx, Home-based unstructured cognitive stimulation
- Where
- 3 sites in Italy
- Volunteers
- 60 people
- Sponsor
- IRCCS Centro San Giovanni di Dio Fatebenefratelli
Caregiver
Mindfulness-based Lifestyle Modification Programme for Caregivers of People With Neurodegenerative Disorders: A Pilot Randomised Controlled Trial
Over 80% of caregivers for individuals with neurodegenerative diseases (ND) engage in significant risk behaviors, particularly physical inactivity, which increases the risk of cardiometabolic diseases (CMD) by 30% and reduces…
- Trial name
- B-Mindful-Life (NCT06583018)
- Testing
- In-Person Mindfulness-based Group Sessions, Ecological Momentary Interventions (EMI), In-person Lifestyle Education Session
- Where
- Hong Kong
- Volunteers
- 87 people
- Sponsor
- The University of Hong Kong
Tuberous Sclerosis Complex, Lymphangioleiomyomatosis
Tuberous Sclerosis Complex and Lymphangioleiomyomatosis Pregnancy Registry (TSC-LAM Registry)
This study is an observational registry designed to gather information about Tuberous Sclerosis Complex (TSC) and Lymphangioleiomyomatosis (LAM) in pregnant women and their child.
- Trial name
- NCT06160310
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- David M. Ritter
Dementia, Caregiver Burnout
Equality in Caregiving: Facilitating Caregiver Mastery Among LGBT Caregivers of PLWD
The goal of this study is to adapt existing Savvy Caregiving Program (SCP) for lesbian, gay, bisexual, transgender (LGBT) caregivers of person living with dementia (PLWD).
- Trial name
- EIC (NCT04394260)
- Testing
- Savvy Caregiver Program via Remote Learning, Focus group
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Emory University
Amyotrophic Lateral Sclerosis
The Effect of RNS60 on ALS Biomarkers
Amyotrophic Lateral Sclerosis (ALS) is a rare lethal neurodegenerative disease involving inflammation. Riluzole, the only drug for ALS, improves median survival by 3 months. This prompts new treatments of ALS.
- Trial name
- RNS60 (NCT03456882)
- Testing
- RNS60
- Where
- 23 sites in United States, Italy
- Volunteers
- 147 people
- Sponsor
- Mario Negri Institute for Pharmacological Research
Parkinson Disease
Study of Dysarthria, and the Appearance of Non-dopaminergic Signs in Idiopathic PARKinson's Disease
Pilot study: Longitudinal follow up of the PRODY-GI cohort for parkinson's disease (PD) Observational study of upper and lower axial symptoms' occurence in 30 PD patients in on and off drug conditions, 30 aged matched control…
- Trial name
- Prodygi-II (NCT03517059)
- Where
- France
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- University Hospital, Lille
Alzheimer Disease
Perturbation Training Reduces Falls in People With Alzheimer's Disease (AD)
This study will examine the overall capacity of people with Alzheimer's disease learning fall-resistant skills from perturbation training.
- Trial name
- STAD (NCT05205980)
- Testing
- Perturbation training
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Georgia State University
Transthyretin Amyloid Polyneuropathy (ATTR-PN)
The Effect Of Tafamidis Meglumine In Transthyretin Amyloid Polyneuropathy Patients
This is a single-arm, open-label, multicenter study designed to evaluate the efficacy, safety, tolerability as well as pharmacodynamics of tafamidis meglumine in ATTR-PN participants in China.
- Trial name
- NCT04828993
- Testing
- tafamidis meglumine
- Where
- 9 sites in China
- Volunteers
- 15 people
- Sponsor
- Pfizer
Parkinson's Disease
Glucose Tolerance in Patients With an Idiopathic Parkinson's Disease
Dysfunction of autonomic nervous system is an important non motor feature of Parkinson' disease (PD). Lewy body formation is widely distributed in hypothalamus and in sympathetic and parasympathetic systems.
- Trial name
- NCT01114321
- Testing
- Protein and calorie controlled diet
- Where
- 2 sites in France
- Volunteers
- 50 people
- Sponsor
- University Hospital, Clermont-Ferrand
Mild Dementia, Moderate Dementia
Touchscreen Technology and Art for People With Dementia in Care Homes
The prevalence of dementia is rapidly growing worldwide, affecting 46.8 million people in 2015. The 2014 Alzheimer's Society report estimated that 311,730 people with dementia were living in care homes in the United Kingdom (UK).
- Trial name
- NCT03773016
- Testing
- Art apps
- Where
- United Kingdom
- Volunteers
- 12 people
- Sponsor
- University of Nottingham
Alzheimer's Disease, Healthy Controls
Development of Eye-movement Based Biomarkers in Alzheimer's Disease
This study aims to develop and validate a sensitive and non-invasive eye-tracking software application. This study will obtain participant responses to brief cognitive tests designed to evaluate several key functions known to be…
- Trial name
- NCT05176704
- Testing
- Eye-Tracking
- Where
- 5 sites in Canada
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- McGill University
Insomnia, Cognitive Dysfunction
Sleep Healthy Using the Internet Mitigating Insomnia to Address Neurocognitive Difficulties (SHUTi MIND)
This randomized controlled trial will evaluate the impact of an Internet-delivered cognitive behavioral therapy for insomnia (CBT-I) intervention on sleep and the extent to which it contributes to cognitive health in individuals…
- Conditions
- Insomnia, Cognitive Dysfunction, Mild Cognitive Impairment, Sleep Initiation and Maintenance Disorders
- Trial name
- NCT05565833
- Testing
- SHUTi OASIS, Patient Education
- Where
- United States
- Volunteers
- 144 people
- Sponsor
- University of Virginia
Parkinson's Disease
Caffeine as a Therapy for Parkinson's Disease
Parkinson's disease is a common neurodegenerative disorder in which patients experience progressive motor disability and many disabling non-motor symptoms.
- Trial name
- NCT01738178
- Testing
- Caffeine
- Where
- 8 sites in Brazil, Canada
- Volunteers
- 119 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Parkinson's Disease
Parkinson's Foundation PD GENEration Genetic Registry
Development of a central repository for PD-related genomic data for future research.
- Trial name
- NCT04994015
- Testing
- Lab Assay for seven genetic variants for Parkinson's Disease
- Where
- 70 sites in United States, Canada and 1 more
- Volunteers
- 35,382 people
- Sponsor
- Parkinson's Foundation
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.